Covered recipient · General Payments record
ERNEST G THOMPSON
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$2,579.60
120 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,579.60 | 120 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $489.56 | 21 |
| GlaxoSmithKline, LLC. | $294.46 | 18 |
| AbbVie Inc. | $269.74 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. | $185.08 | 10 |
| Novo Nordisk Inc | $173.09 | 5 |
| Daiichi Sankyo Inc. | $167.58 | 4 |
| Janssen Pharmaceuticals, Inc | $120.16 | 3 |
| Supernus Pharmaceuticals, Inc. | $103.51 | 5 |
| DEXCOM, INC. | $103.31 | 2 |
| PFIZER INC. | $71.12 | 4 |
| JAZZ PHARMACEUTICALS INC. | $66.25 | 3 |
| Merck Sharp & Dohme Corporation | $65.70 | 5 |
| Bayer HealthCare Pharmaceuticals Inc. | $63.16 | 1 |
| Novartis Pharmaceuticals Corporation | $56.15 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $45.56 | 3 |
| Lilly USA, LLC | $41.25 | 3 |
| Astellas Pharma US Inc | $40.21 | 3 |
| Avanir Pharmaceuticals, Inc. | $36.22 | 2 |
| ITI, Inc. | $30.55 | 2 |
| Eisai Inc. | $24.42 | 1 |
| Philips Electronics North America Corporation | $23.41 | 1 |
| Amarin Pharma Inc. | $21.51 | 1 |
| Vanda Pharmaceuticals Inc. | $19.21 | 1 |
| E.R. Squibb & Sons, L.L.C. | $18.78 | 1 |
| Adlon Therapeutics L.P. | $18.08 | 1 |
| Abbott Laboratories | $16.90 | 1 |
| ARBOR PHARMACEUTICALS, INC. | $14.63 | 1 |
Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ERNEST G THOMPSON
NPI 1841212610 · CMS profile ID 37517
Allopathic & Osteopathic Physicians / Internal Medicine
BAKER, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1841212610?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ERNEST G THOMPSON, NPI 1841212610, CMS profile ID 37517. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841212610?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). ERNEST G THOMPSON, NPI 1841212610, CMS profile ID 37517. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841212610?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- ERNEST G THOMPSON, NPI 1841212610, CMS profile ID 37517, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1841212610?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
120 matching records · $2,579.60 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 120.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $17.57 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802822467 | CMS |
| AbbVie Inc. | $21.07 | 07/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796153143 | CMS |
| Novo Nordisk Inc | $3.36 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811322880 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.78 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820302857 | CMS |
| Supernus Pharmaceuticals, Inc. | $17.51 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845124353 | CMS |
| GlaxoSmithKline, LLC. | $14.83 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802075403 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.50 | 07/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763339222 | CMS |
| Novo Nordisk Inc | $7.69 | 06/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810794009 | CMS |
| GlaxoSmithKline, LLC. | $18.03 | 06/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802565001 | CMS |
| Amgen Inc. | $17.72 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825305181 | CMS |
| AbbVie Inc. | $19.13 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796153141 | CMS |
| JAZZ PHARMACEUTICALS INC. | $21.55 | 06/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845628697 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.50 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820302853 | CMS |
| Novartis Pharmaceuticals Corporation | $14.71 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813313645 | CMS |
| Novo Nordisk Inc | $21.77 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811707027 | CMS |
| Supernus Pharmaceuticals, Inc. | $19.55 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845124347 | CMS |
| Amgen Inc. | $20.98 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825305241 | CMS |
| DEXCOM, INC. | $17.18 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845301643 | CMS |
| PFIZER INC. | $17.96 | 06/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833386419 | CMS |
| Avanir Pharmaceuticals, Inc. | $16.70 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801029875 | CMS |
| GlaxoSmithKline, LLC. | $15.38 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802599711 | CMS |
| Lilly USA, LLC | $13.20 | 05/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819139409 | CMS |
| AbbVie Inc. | $20.00 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796153139 | CMS |
| GlaxoSmithKline, LLC. | $14.61 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802239203 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.45 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820302849 | CMS |
| Novartis Pharmaceuticals Corporation | $18.58 | 05/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813313641 | CMS |
| Supernus Pharmaceuticals, Inc. | $23.43 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845124343 | CMS |
| GlaxoSmithKline, LLC. | $15.74 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802854235 | CMS |
| Avanir Pharmaceuticals, Inc. | $19.52 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801033773 | CMS |
| AbbVie Inc. | $24.38 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796153137 | CMS |
| GlaxoSmithKline, LLC. | $14.57 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802967781 | CMS |
| Lilly USA, LLC | $13.90 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819143897 | CMS |
| AbbVie Inc. | $7.80 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796153135 | CMS |
| Amgen Inc. | $10.34 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825305205 | CMS |
| Amgen Inc. | $18.65 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825305237 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.72 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763339224 | CMS |
| AbbVie Inc. | $14.24 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796153133 | CMS |
| GlaxoSmithKline, LLC. | $18.89 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803035123 | CMS |
| GlaxoSmithKline, LLC. | $15.22 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801897463 | CMS |
| Merck Sharp & Dohme Corporation | $12.51 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848492059 | CMS |
| AbbVie Inc. | $23.33 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796153131 | CMS |
| Novo Nordisk Inc | $15.27 | 03/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811707023 | CMS |
| Amgen Inc. | $20.33 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825305233 | CMS |
| Merck Sharp & Dohme Corporation | $12.09 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848622587 | CMS |
| PFIZER INC. | $16.77 | 03/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833556067 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $7.33 | 03/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820302845 | CMS |
| Amgen Inc. | $10.57 | 03/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826334513 | CMS |
| GlaxoSmithKline, LLC. | $13.45 | 03/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802211451 | CMS |
| Supernus Pharmaceuticals, Inc. | $23.86 | 03/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845124339 | CMS |
| ARBOR PHARMACEUTICALS, INC. | $14.63 | 03/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830948485 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $552,184.85 | 19 |
| PY2024 | Principal investigator | $417,680.88 | 19 |
| PY2023 | Principal investigator | $350,251.21 | 26 |
| PY2022 | Principal investigator | $227,693.53 | 20 |
| PY2021 | Principal investigator | $202,808.94 | 20 |
| PY2020 | Principal investigator | $163,355.75 | 10 |
| PY2019 | Principal investigator | $133,994.80 | 15 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
19 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 12/17/2025 | Non-covered Recipient Entity Southern Clinical Research-Louisiana | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220767527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 12/17/2025 | Non-covered Recipient Entity Southern Clinical Research-Louisiana | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220767529 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,598.00 | 12/10/2025 | Non-covered Recipient Entity Southern Clinical Research LLC | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215507968 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $10,000.00 | 12/10/2025 | Non-covered Recipient Entity Southern Clinical Research LLC | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215507972 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,354.53 | 09/08/2025 | Non-covered Recipient Entity SOUTHERN CLINIC RESEARCH CLINIC | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190306325 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,233.82 | 08/27/2025 | Non-covered Recipient Entity SOUTHERN CLINICAL RESEARCH, LLC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185547395 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $54,221.00 | 08/21/2025 | Non-covered Recipient Entity SOUTHERN CLINIC RESEARCH CLINIC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190300755 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $26,285.06 | 08/21/2025 | Non-covered Recipient Entity SOUTHERN CLINIC RESEARCH CLINIC | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190300759 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,198.37 | 08/19/2025 | Non-covered Recipient Entity SOUTHERN CLINIC RESEARCH CLINIC | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190300753 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,100.11 | 08/19/2025 | Non-covered Recipient Entity SOUTHERN CLINIC RESEARCH CLINIC | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190300757 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $148,048.06 | 07/31/2025 | Non-covered Recipient Entity SOUTHERN CLINICAL RESEARCH, LLC | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event | No dispute reported | 06/30/2026 | 1185547397 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,855.73 | 05/01/2025 | Non-covered Recipient Entity SOUTHERN CLINIC RESEARCH CLINIC | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190306331 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $64,793.47 | 02/04/2025 | Non-covered Recipient Entity SOUTHERN CLINIC RESEARCH CLINIC | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190306329 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $32,377.27 | 01/30/2025 | Non-covered Recipient Entity SOUTHERN CLINIC RESEARCH CLINIC | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190306321 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,750.00 | 01/29/2025 | Non-covered Recipient Entity SOUTHERN CLINICAL RESEARCH, LLC | A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON | No dispute reported | 06/30/2026 | 1185547391 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $64,430.94 | 01/27/2025 | Non-covered Recipient Entity SOUTHERN CLINIC RESEARCH CLINIC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190306323 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,185.56 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CLINICAL RESEARCH, LLC | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations | No dispute reported | 06/30/2026 | 1185547393 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $27,259.75 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CLINICAL RESEARCH, LLC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185547399 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $43,050.94 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CLINIC RESEARCH CLINIC | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190306327 |